Clinical Trial Update: Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the effect of somatropin on linear growth and final height in individuals with Noonan syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noonan Syndrome

Drugs mentioned

• Somatropin (somatropin)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Genetic Disorder, Noonan Syndrome | Phase 3 | Status: COMPLETED